# Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

> **NCT04402788** · PHASE2,PHASE3 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 138 (estimated)

## Conditions studied

- Extensive Stage Lung Small Cell Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT04402788
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-07
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04402788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04402788, "Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT04402788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*